Infra-Hisian Block: Difference between revisions

Jump to navigation Jump to search
Line 17: Line 17:
==Pathophysiology==
==Pathophysiology==


Mobitz type II second degree AV block Mobitz type II second degree AV block (waveform 2), in which the PR interval remains unchanged prior to a P wave that fails to conduct to the ventricles.
Mobitz type II second degree AV block Mobitz type II second degree AV block, in which the PR interval remains unchanged prior to a P wave that fails to conduct to the ventricles.
It almost always results from conduction system disease below the level of the AV node (figure 1), occurring in the bundle of His in approximately 20 percent of cases and in the bundle branches in the remainder [3]. Patients with bundle branch involvement also have axis shifts and QRS widening depending upon the location of the block. In addition, at least two-thirds of patients with this disorder also have bifascicular or even trifascicular disease
It almost always results from conduction system disease below the level of the AV node, occurring in the bundle of His in approximately 20 percent of cases and in the bundle branches in the remainder. Patients with bundle branch involvement also have axis shifts and QRS widening depending upon the location of the block. In addition, at least two-thirds of patients with this disorder also have bifascicular or even trifascicular disease.
Mobitz type I and Mobitz type II second degree AV block cannot be differentiated from the ECG when 2:1 AV block is present. In this situation, every other P wave is non-conducted and there is no opportunity to observe for the constant PR interval that is characteristic of Mobitz type II second degree AV block.


==Causes==
==Causes==

Revision as of 22:29, 21 April 2020

WikiDoc Resources for Infra-Hisian Block

Articles

Most recent articles on Infra-Hisian Block

Most cited articles on Infra-Hisian Block

Review articles on Infra-Hisian Block

Articles on Infra-Hisian Block in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Infra-Hisian Block

Images of Infra-Hisian Block

Photos of Infra-Hisian Block

Podcasts & MP3s on Infra-Hisian Block

Videos on Infra-Hisian Block

Evidence Based Medicine

Cochrane Collaboration on Infra-Hisian Block

Bandolier on Infra-Hisian Block

TRIP on Infra-Hisian Block

Clinical Trials

Ongoing Trials on Infra-Hisian Block at Clinical Trials.gov

Trial results on Infra-Hisian Block

Clinical Trials on Infra-Hisian Block at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Infra-Hisian Block

NICE Guidance on Infra-Hisian Block

NHS PRODIGY Guidance

FDA on Infra-Hisian Block

CDC on Infra-Hisian Block

Books

Books on Infra-Hisian Block

News

Infra-Hisian Block in the news

Be alerted to news on Infra-Hisian Block

News trends on Infra-Hisian Block

Commentary

Blogs on Infra-Hisian Block

Definitions

Definitions of Infra-Hisian Block

Patient Resources / Community

Patient resources on Infra-Hisian Block

Discussion groups on Infra-Hisian Block

Patient Handouts on Infra-Hisian Block

Directions to Hospitals Treating Infra-Hisian Block

Risk calculators and risk factors for Infra-Hisian Block

Healthcare Provider Resources

Symptoms of Infra-Hisian Block

Causes & Risk Factors for Infra-Hisian Block

Diagnostic studies for Infra-Hisian Block

Treatment of Infra-Hisian Block

Continuing Medical Education (CME)

CME Programs on Infra-Hisian Block

International

Infra-Hisian Block en Espanol

Infra-Hisian Block en Francais

Business

Infra-Hisian Block in the Marketplace

Patents on Infra-Hisian Block

Experimental / Informatics

List of terms related to Infra-Hisian Block

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief: Sara Mohsin, M.D.[2]

Overview

Infra-Hisian blocks are defined as impaired conduction in the electrical system of the heart that occur below the AV node.

Classification

Infrahisian block describes block of the distal conduction system. Types of infrahisian block include:

Of these types of infrahisian block, Mobitz II heart block is considered most important because of the possible progression to complete heart block.

Pathophysiology

Mobitz type II second degree AV block Mobitz type II second degree AV block, in which the PR interval remains unchanged prior to a P wave that fails to conduct to the ventricles. It almost always results from conduction system disease below the level of the AV node, occurring in the bundle of His in approximately 20 percent of cases and in the bundle branches in the remainder. Patients with bundle branch involvement also have axis shifts and QRS widening depending upon the location of the block. In addition, at least two-thirds of patients with this disorder also have bifascicular or even trifascicular disease. Mobitz type I and Mobitz type II second degree AV block cannot be differentiated from the ECG when 2:1 AV block is present. In this situation, every other P wave is non-conducted and there is no opportunity to observe for the constant PR interval that is characteristic of Mobitz type II second degree AV block.

Causes

The potential etiologies of Mobitz type II second degree AV block include reversible (both pathologic and iatrogenic) and idiopathic causes that are similar to other degrees of AV block (table 1). Common potentially reversible causes include:

●Pathologic – Myocardial ischemia (acute or chronic) involving the conduction system, cardiomyopathy (eg, amyloidosis, sarcoidosis), myocarditis (eg, Lyme disease), endocarditis with abscess formation, hyperkalemia, and hypervagotonia.

●Iatrogenic – Medication-related (AV nodal blocking medications), post-cardiac surgery, post-catheter ablation, post-transcatheter aortic valve implantation.

Mobitz type II second degree AV block is rarely seen in patients without underlying heart disease. When identifiable, the reversible causes most commonly associated with Mobitz type II second degree AV block are myocardial infarction with ischemia of the AV node and medications that alter conduction through the AV node (eg, digoxin, beta blockers, calcium channel blockers). When no specific reversible cause is identified, the block is often felt to be related to idiopathic progressive cardiac conduction disease with myocardial fibrosis and/or sclerosis that affects the conduction system.

Differentiating ((Page name)) from other Diseases

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].

Epidemiology and Demographics

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.

OR

In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

OR

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.


Patients of all age groups may develop [disease name].

OR

The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.

OR

[Disease name] commonly affects individuals younger than/older than [number of years] years of age.

OR

[Chronic disease name] is usually first diagnosed among [age group].

OR

[Acute disease name] commonly affects [age group].


There is no racial predilection to [disease name].

OR

[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].


[Disease name] affects men and women equally.

OR

[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


The majority of [disease name] cases are reported in [geographical region].

OR

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Risk Factors

There are no established risk factors for [disease name].

OR

The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

OR

Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications, and Prognosis

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with [disease name].

OR

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

References


Template:WS Template:WH